Objective: Juvenile myoclonic epilepsy (JME) is a common adolescent-onset genetic generalized epilepsy (GGE) syndrome. Multiple linkage and association studies have found that BRD2 influences the expression of JME. The BRD2-JME connection is further corroborated by our murine model; Brd2 haploinsufficiency produces characteristics that typify the clinical hallmarks of JME. Neither we, nor several large-scale studies of JME, found JME-related BRD2 coding mutations. Therefore, we investigated noncoding BRD2 regions, seeking the origin of BRD2's JME influence. BRD2's promoter harbors a JME-associated single nucleotide polymorphism (rs3918149) and a CpG (C-phosphate-G dinucleotides) island (CpG76), making it a potential "hotspot" for JME-associated epigenetic variants. Methylating promoter CpG sites causes gene silencing, often resulting in reduced gene expression. We tested for differences in DNA methylation at CpG76 in 3 different subgroups: (1) JME patients versus their unaffected family members, (2) JME versus patients with other forms of GGE, and (3) Caucasian versus non-Caucasian JME patients.
| INTRODUCTION
Juvenile myoclonic epilepsy (JME; Online Mendelian Inheritance in Man database 608816), the most common of the adolescent onset generalized epilepsy syndromes, has a prevalence of~1 in 1000 people worldwide (National Institutes of Health).
1 JME is characterized clinically by involuntary myoclonic jerks (mostly on awakening). The interictal electroencephalogram (EEG) in untreated patients shows bursts of generalized spikes and waves, often at a frequency of 4-6 Hz. 2, 3 Although most patients respond to pharmacological treatment, the frequency of symptom recurrence is high when antiepileptic medication is discontinued. 4 JME is highly familial. Our group originally reported strong linkage of a JME-related gene locus at 6p21, the region containing BRD2. 5 Association analysis pointed to the BRD2 gene as the best-supported candidate. [6] [7] [8] The JME-6p21 linkage was confirmed multiple times. [8] [9] [10] Other studies showed the region (and later the BRD2 gene) to be related to the expression of abnormal EEG patterns. 11 6p21
shows linkage to the photoparoxysmal response, 12 and follow-up studies showed association of single nucleotide polymorphisms (SNPs) in BRD2 with photosensitivity. 13 It is important to note that the BRD2-JME linkage appeared to be ethnicity dependent 8, 10 and specific to Caucasians.
Recently, Santos et al, 14 in a systematic review on genetic associations in JME using PRISMA guidelines, recognized BRD2 as a significant JME causative/susceptibility gene. The JME-BRD2 link in humans is strongly corroborated by studies of the JME mouse model. This model, in which 1 Brd2 allele is nonfunctional (Brd2+/À), recapitulates the JME phenotype with remarkable fidelity. The mouse data show that Brd2 haploinsufficiency causes increased seizure susceptibility, spontaneous seizures, abnormal interictal EEGs, and other JME hallmarks. 15 The proximate neuroanatomical cause appears to be related to a deficit of specific c-aminobutyric acidergic (GABAergic) neurons in certain seizure-related brain regions in the basal ganglia pathway, that is, neocortex and striatum. 15 That an insufficiency of Brd2 in mice causes a JME-like phenotype implies that, in humans, it is a deficit of BRD2 that contributes to JME susceptibility. However, we have not found disease-related exonic mutations in human BRD2 that are associated with JME or even that affect BRD2 gene expression, nor have any been reported (Genetic Testing Registry, accessed on January 5, 2018). Because no JME-related exonic mutations have been reported, and JME is a common epileptic syndrome, it is likely that sequence variants leading to seizure susceptibility are in the noncoding, control regions of BRD2. We have identified one such noncoding region within the BRD2 promoter, one that harbors a JME-associated SNP (rs3918149) and a C-phosphate-G (CpG) island ( Figure 1 ). CpG islands are clusters of CpG dinucleotides; they are usually nonmethylated. But methylation of CpG islands in the promoter of a gene modulates the gene's expression. DNA methylation is known to play a critical role in brain function and behavior, and dysregulated methylation is a cause of disease. 16 Because DNA methylation leads to altered gene expression, it may underlie changes in BRD2 expression that lead to epileptogenesis in JME via changes in neuronal excitability or changes in neuronal populations (as suggested by our mouse model studies). A growing number of human and murine studies have shown the importance of DNA methylation in epilepsy susceptibility (reviewed in Kobow and Blumcke 17 ). These epigenetic DNA methylation alterations could contribute to JME susceptibility and development/maintenance of JME. Experiments have shown that methylation of the promoter CpG sites in BRD2 can lead to gene silencing. During adipocyte differentiation, DNA methylation status of the CpG island in BRD2's promoter changes BRD2 expression. 18 Because the CpG island in the BRD2 promoter also harbors a JME-associated promoter SNP (rs3918149), 6 the BRD2 promoter is a "hotspot" for possible JME-associated epigenetic variants.
In the present study, we tested whether DNA methylation of the BRD2 promoter (and therefore a possible deficit of BRD2 transcription) is related to the JME phenotype. We asked the following questions: (1) Do JME patients show altered BRD2 promoter methylation compared to family members without JME? (2) Do BRD2 promoter methylation changes within families cosegregate with JME? (3) Do patients diagnosed with genetic generalized epilepsy (GGE) that are not JME have altered BRD2
Key Points
• DNA methylation status at the BRD2 promoter, as well as global methylation, was analyzed in lymphoblastoid cells from JME patients, and from unaffected family members, of both Caucasian and non-Caucasian origin, and also from non-JME GGE patients
• JME segregates together with BRD2 promoter methylation in Caucasians
• Non-JME GGE and non-Caucasian JME families do not show such segregation
• Global methylation levels do not differ in JME patients compared to unaffected family members, showing that BRD2 promoter methylation is specifically related to JME expression promoter methylation patterns? (4) Do non-Caucasian JME patients show the same BRD2 promoter methylation pattern as Caucasian JME patients?
| MATERIALS AND METHODS

| Participants
Our study included the GGE cohort, including JME and non-JME GGE patients, together with their participating family members. 8 These subjects were ascertained in North America, mostly from the East Coast cities of the USA, and collected between 1992 and 2005. The JME probands were diagnosed in accordance with international classification guidelines (Commission on Classification and Terminology of the International League Against Epilepsy 1989) as described by Greenberg et al. 8 A cohort of non-JME GGEs was collected at the same time from the same sources, as described elsewhere. 8 
| DNA preparation
The blood samples were collected from the patients and family members. Buffy coats were transformed to establish B-cell lymphoblastoid cell lines and kept frozen in liquid nitrogen. DNA was extracted from established cultures of lymphoblastoid cell lines using Wizard Genomic DNA purification kit (Promega, Madison, WI, USA).
| DNA Pyrosequencing
One microgram of DNA was subjected to bisulfite treatment using EZ DNA Methylation-Gold kit (Zymo Research, Orange, CA, USA) following the manufacturer's protocol. For pyrosequencing-based methylation analysis of CpG76, the bisulfite-modified DNA was polymerase chain reaction (PCR)-amplified using the biotinylated primers (Qiagen, Valencia, CA, USA) shown in Table 1 . The biotinylated PCR products were purified using the Sepharose beads and denatured with 0.2 molÁL -1 NaOH solution using the pyrosequencing vacuum prep tool. Subsequently, 0.3 µmolÁL -1 pyrosequencing primer (Table 1 ) was annealed to the purified single-stranded PCR product and sequencing was carried out using MD96 pyrosequencing System (Qiagen). Quantitation of cytosine methylation was carried out using PyroMark96 software. The methylated and unmethylated human control DNA (Qiagen) was used to verify bisulfite conversion.
| Global methylation
Global methylation levels of lymphoblastoid cell DNA were measured using the Methylflash Global DNA Methylation ELISA Easy kit (Epigentek, Brooklyn, NY, USA) following the manufacture's recommendations. Briefly, 100 ng of genomic DNA was used for 5-methyl cytosine (5-mC) quantitation. The input DNA was washed and incubated with a capture antibody. The wells were then washed, and detection antibody was applied. Use of enhancer solution and development solution created a color change proportional to the quantity of 5-mC content, and the samples were read colorimetrically on an automated plate reader at 450-nm absorbance. The use of a standard curve enabled the quantification of 5-mC based on absorbance measurements.
| Quantitative real-time PCR
Total RNA was extracted from patient-derived lymphoblastoid cells using RNeasy mini kit and converted into cDNA by iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's recommendations. Quantitative real-time PCR analysis was performed using Taqman probes for DNA methyl transferase 1 (DNMT1)-Hs00154749 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-Hs02758991_g1 (Applied Biosystems, Foster City, CA, USA) on Realplex Mastercycler (Eppendorf, Hamburg, Germany). Expression relative to GAPDH was calculated using 2 DDC t .
| Statistical methods
The data analyses were performed using Excel 2011 (Microsoft, Redmond, WA, USA), Prism 7 (version 7.0a; GraphPad Software, La Jolla, CA, USA), and R software. Pyrosequencing data in triplicates are expressed in percentage methylation and differences in percentage methylation were tested for statistical significance at the 1% level based on a Student t test/1-way analysis of variance, and a nonparametric bootstrap procedure. 19 Because biologically 3 | RESULTS 3.1 | CpG76 is methylated in the DNA from lymphoblasts of Caucasian JME patients
Using pyrosequencing, we tested the hypothesis that the JME phenotype is related to DNA methylation of the BRD2 promoter by measuring the level of CpG76 methylation in the lymphoblastoid cells from Caucasian JME patients and from unaffected family members. We initially tested specifically Caucasian JME families for BRD2 promoter methylation based on the evidence that the BRD2-JME connection exists (primarily) in families of European origin. 8 We designed 3 pyrosequencing assays covering 10
CpG sites at CpG76 within the BRD2 promoter ( Figure 1 and Table 1 ). We pyrosequenced 23 JME patients, some of whom were related, and 23 of the unaffected family members from those families. The pyrosequencing analysis revealed a markedly bimodal distribution for percentage methylation in JME patients (n = 23; Figure 2A [red dots]), and an apparently unimodal distribution for their unaffected family members (n = 23; Figure 2A [blue squares]). This suggests that BRD2 is influencing JME in some (but not all) of our JME patients, which is consistent with our previous findings 20 of heterogeneity in JME. To identify those families where BRD2 is likely involved, we stratified our affected families into 2 groups based on whether there was increased sharing of genetic material (ie, positive evidence of linkage). In the linked families, we found that the percentage difference in methylation between JME patients and their unaffected family members was statistically significant ( Figure 2B ; P < .0001). Conversely, in the unlinked families, the difference in percentage methylation was not statistically significant ( Figure 2C ). These data indicate that JME segregates together with DNA methylation status in the BRD2 promoter region, and that JME is a heterogeneous disease.
3.2 | CpG76 is unmethylated in non-JME
GGE patients
Our previous data show that non-JME forms of GGEs are not linked or associated with the BRD2 locus. 21 We analyzed methylation of CpG76 in the BRD2 promoter in patients with epilepsy with tonic-clonic seizures (random grand mal [RGM]), awakening grand mal (AGM), and juvenile absence epilepsy (JAE) patients. These patients did not have myoclonic jerks as part of their clinical presentation, according to their medical records, their own report, and those of their family members. Pyrosequencing analysis of 7 RGM, 4 AGM, and 5 JAE patients revealed methylation levels similar to those of unaffected JME family members, that is, there was no evidence of JME-level methylation at the BRD2 promoter ( Figure 3A ). Non-JME GGE families also showed little evidence of segregation of genetic markers with affectedness. 20 These latest data corroborate earlier findings that BRD2 is not linked to non-JME forms of GGE and support the finding that seizure-related changes in the BRD2 promoter are JME-specific.
| CpG76 is unmethylated in non-
Caucasian JME patients
Our earlier studies revealed that an SNP (rs3918149) located in CpG76 showed a significant association with JME in Caucasian Europeans 6,7 but no association in Tunisian 22 or Southern Indian populations. We therefore asked whether the JME-specific BRD2 promoter methylation we observed is associated with ethnicity. CpG76 methylation was examined in Hispanic, African American (AA), and mixed-ethnicity JME families (such as Hispanic-AA, Caucasian-Hispanic, and Caucasian-Hispanic-AA), all diagnosed according to the same clinical criteria as the Caucasian JME patients. There was no difference in methylation patterns comparing non-Caucasian JME patients and their unaffected family members ( Figure 3B ). This finding supports our past work showing that BRD2 is linked to JME only in Caucasians. 8 That 5 of the 25 non-Caucasian JME patients, all Hispanic, showed high levels of methylation similar to Caucasian JME patients further underlines the importance of genetic heterogeneity within GGE. 23 
| Global methylation levels are similar in
Caucasian JME patients and family members Altered methylation levels of the BRD2 promoter in Caucasian JME patients could be due to alterations in global methylation of B-lymphoblastoid cells. Global methylation patterns are maintained by the enzyme DNMT1. Hence, we measured global methylation levels using a 5-methyl cytosine-based immunoassay platform and DNMT1 transcripts by quantitative PCR. No significant difference in genome-wide 5-mC levels ( Figure 4A ) and DNMT1 transcripts ( Figure 4B ) was observed between JME patients and unaffected family members.
| DISCUSSION
JME was the first form of epilepsy for which a genetic locus was confirmed, demonstrating JME's genetic origin, 24 and linkage and association analyses from different research groups over the past 3 decades have established BRD2 as a major genetic component for JME (see Santos et al 14 for a review).
In this section, we expand on the following:
1. What is BRD2? 2. BRD2 methylation and suppression of protein expression. 3. The effect of ethnicity, type of GGE, and cosegregation of JME and BRD2. 4. Valproic acid (VPA) affects methylation. 5. The JME methylation finding is not because of changes in global methylation levels.
F I G U R E 2 Status of DNA methylation of the BRD2 promoter in human families identified through a juvenile myoclonic epilepsy (JME) patient. A, A box plot showing CpG 76 methylation levels in Caucasian JME patients and unaffected family members. B, Caucasian JME patients with positive evidence of linkage to BRD2 and unaffected family members. C, Caucasian JME patients without positive linkage evidence to BRD2 and unaffected family members. Data are represented as mean AE standard error of the mean. *Significant comparison F I G U R E 3 DNA methylation analysis of CpG76 by pyrosequencing on DNA from lymphoblastoid cells in Caucasian non-juvenile myoclonic epilepsy (JME) genetic generalized epilepsy patients (A) and non-Caucasian JME families (B). AGM, awakening grand mal; RGM, random grand mal
| What is BRD2?
BRD2, a bromodomain containing transcriptional activator, is involved in cell cycle, growth, proliferation, and apoptosis. It is also an essential developmental gene; Brd2's absence in mice (Brd2À/À) leads to profound neurodevelopmental failure and early in utero demise. 25, 26 Heterozygous mice (BRD2+/À) are viable and display a startlingly JME-like phenotype, including spontaneous generalized seizures, increased seizure susceptibility to flurothyl after puberty, female preponderance, and JME-associated behavioral traits, as well as brain region and sex-specific GABAergic system anomalies. 15 The compelling mouse-human phenotype similarities also suggest that JME is, at its core, a neurodevelopmental disorder.
| BRD2 methylation and suppression of protein expression
Our current study shows that JME segregates together with a BRD2 methylation variant in the promoter region, a variant that probably leads to reduced BRD2 production. DNA methylation of gene promoters is tightly correlated with transcription suppression, yet the mechanism for such suppression is still unclear. 27, 28 Multiple studies have shown a negative association between the level of DNA methylation in promoters and the expression of downstream genes. 18, 29 Aberrant promoter methylation at the BRD2 locus would most likely result in a BRD2 deficit. We hypothesize that the BRD2 deficit leads to seizure susceptibility due to a BRD2-deficit-caused decrease in specific GABAergic neuronal populations in the brain, as suggested by our mouse model. Also, the linkage evidence 5, [8] [9] [10] shows that, at the BRD2 locus, JME is dominantly inherited. This supports the idea that one of the inherited alleles has reduced production of the BRD2 protein.
Growing evidence from the human and murine studies has highlighted the role of DNA methylation in epilepsy susceptibility (reviewed in Kobow and Blumcke 17 ). For instance, Kobow et al 30 found that increased levels of DNA methylation in the promoter region of reelin are associated with the pathogenesis of temporal lobe epilepsy patients. Increased methylation at the CPA6 promoter has also been found in patients with focal epilepsy and in febrile seizures. 31 Furthermore, the neuron-restrictive silencing factor, which regulates neuronal gene expression and recruits methylating enzymes, is involved in seizure development and progression. 32 Recently, genome-wide as well as gene-specific alterations in DNA methylation have been reported in epilepsy pathogenesis (reviewed in Kobow and Blumcke 17 ). To our knowledge, this is the first study to report that aberrant DNA methylation is associated with a GGE phenotype. The dynamics of the DNA methylation mechanism may provide an explanation for some features of JME, including adolescent onset timing and possible maternal inheritance.
8,33
As we noted, the JME-associated SNP rs3918149 is located in the CpG76 island within the BRD2 promoter region. SNPs associated with promoter CpG islands show correlation with gene expression. 34 Hence, it is possible that methylation of rs3918149 itself in CpG76 has a role regulating BRD2 transcript abundance in brain.
4.3 | The effect of ethnicity, type of GGE, and cosegregation of JME and BRD2
We observed aberrant methylation of the BRD2 promoter only in Caucasian JME patients and then only in families that show positive evidence of linkage to BRD2, that is, cosegregation of JME with genetic markers in the region. We did not see methylation in patients from families that showed evidence against linkage to the region, nor in patients from JME families that were not of Caucasian background. It is well documented that DNA methylation profiles differ in different populations. 35 Such differences F I G U R E 4 Global DNA methylation in juvenile myoclonic epilepsy (JME) patients and unaffected family members. A, A box plot showing global DNA methylation levels (represented by total 5-methyl-cytosine or 5-mC%) by enzyme-linked immunosorbent assay on DNA from Caucasian JME patients and unaffected family members. B, Normalized DNMT1 gene expression was measured by quantitative real-time polymerase chain reaction in lymphoblasts from JME patients and unaffected family members. Data were normalized to glyceraldehyde-3-phosphate dehydrogenase may contribute to ethnically based disease susceptibilities differences. 36 The underlying reason for racial differences in DNA methylation, at BRD2 or anywhere in the genome, is not known. The ethnicity-based methylation differences we observed may reflect variation in brain environment, brain metabolism, or genomic signals for methylation. Irrespective of mechanism, we hypothesize that methylated BRD2 in Caucasian JME patients may indicate an ethnicityspecific etiologic pathway for development of epilepsy.
The diagnosis-dependent differences we observed also emphasize the importance of carefully differentiating different forms of disease to identify the specific genes involved in disease etiology. The recent trend in studying the genetic origins of many common diseases is to classify all forms of disease as though they had the same genetic basis. This classification approach has led to false starts and wasted resources. 20, 23 Our work on methylation also shows that the noncoding regions of the genome can also contribute to common epilepsy susceptibility. Although approaches to understanding how the noncoding regions can affect disease expression are only beginning to be developed, our work shows that gaining such understanding is essential for understanding disease etiology.
| VPA affects methylation
In a majority of patients with JME, seizures are well controlled with VPA, with a response rate of up to 80% 37 (although, due to the side effects associated with VPA use, the popularity of the drug has decreased over time as alternatives have become available). It may not be a coincidence that VPA is a histone deacetylase inhibitor and regulates DNA methylation. 38 Although VPA has been shown to cause DNA demethylation 38 (thus hypothetically counteracting the highly methylated BRD2 promoter in JME patients), the Caucasian JME patients in our cohort who received VPA treatment still showed high methylation levels of the promoter. Thus, it is unlikely that medication status affected our results.
4.5 | The JME methylation finding is not because of changes in global methylation levels A previous study also suggested a link between BRD2 and DNA methylation. Depletion of BRD2 in HeLa cells by small interfering RNA resulted in~2.5-fold increased expression of DNMT1. 39 DNMT1 has an important role in the maintenance of the tissue-specific DNA methylation patterns. 40 The aberrant methylation signature in some JME patients of Caucasian origin prompted us to analyze DNMT1 expression and global methylation. We did not observe any change in global methylation level and DNMT1 expression in the lymphoblasts between JME patients and unaffected family members. Thus, the loss of methylation at the BRD2 promoter in the lymphoblasts of JME patients is locus-specific and associated with JME expression. The brain tissue from well-diagnosed JME patients is unavailable, so we cannot determine whether human JME patients have a brain localized BRD2 deficit. Therefore, we have used patient-derived lymphoblastoid lines for DNA methylation evaluation of the BRD2 promoter. Several studies have reported that disease-associated DNA methylation abnormalities can be detected in different tissues. 41 One question is how much methylation patterns change in different tissues. There are tissue-specific variations in DNA methylation patterns, 34,42 so we sought to answer the question as to whether changes in lymphocyte methylation patterns mirror changes in the brain. We correlated promoter CpG sites in the lymphocytes with those in brain in silico, using a Web-based BECon tool. 43 We found that 6 of 20
promoter CpG sites were correlated in the 2 tissues (correlation > 0.3) in at least 1 of the 3 examined brain regions (Table 2) , indicating conservation of epigenetic function. These results suggest there is a proportion of CpGs for which methylation estimations in blood are representative of methylation in brain and BRD2 promoter methylation in the blood could be used as a surrogate for brain tissue.
| CONCLUSIONS
The results of the present study show evidence that BRD2 promoter methylation variation is a cause of JME in Caucasians, and perhaps in other ethnicities. Identification of the variants that affect BRD2 production might be used to predict JME susceptibility, as well as to improve the ability to diagnose JME.
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